MDT

97.79

-1.28%↓

141.24

-3.25%↓

VEEV

221.27

+0.94%↑

HQY

86.08

-3.24%↓

NEOG

9.23

-2.43%↓

MDT

97.79

-1.28%↓

141.24

-3.25%↓

VEEV

221.27

+0.94%↑

HQY

86.08

-3.24%↓

NEOG

9.23

-2.43%↓

MDT

97.79

-1.28%↓

141.24

-3.25%↓

VEEV

221.27

+0.94%↑

HQY

86.08

-3.24%↓

NEOG

9.23

-2.43%↓

MDT

97.79

-1.28%↓

141.24

-3.25%↓

VEEV

221.27

+0.94%↑

HQY

86.08

-3.24%↓

NEOG

9.23

-2.43%↓

MDT

97.79

-1.28%↓

141.24

-3.25%↓

VEEV

221.27

+0.94%↑

HQY

86.08

-3.24%↓

NEOG

9.23

-2.43%↓

Strona główna・Stock List・Voyager Therapeutics Inc

Voyager Therapeutics Inc

Open

3.89 -2.26

Buy Sell

Overview

Share price change

24h

Current

Min

3.71

Max

3.98

Key metrics
By Trading Economics
Income	5.5M -28M
Sales	8.2M 13M
Profit margin	-208.694
Employees	172
EBITDA	8.7M -27M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+228.36% upside

Dividends
By Dow Jones
Next Earnings	10 mar 2026

Market Stats
By TradingEconomics
Market Cap	-38M 217M
Previous open	6.15
Previous close	3.89

Technical Score

By Trading Central

Confidence

Bearish Evidence

3.17 / 3.4644 Support & Resistance

Voyager Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

15 sty 2026, 18:44 UTC

Major Market Movers

Agenus Falls After $141 Million Zydus Deal Closes

15 sty 2026, 17:51 UTC

Major Market Movers

Galaxy Digital Climbs on Texas Data-Center Expansion Approval, Tokenized CLO Issuance

15 sty 2026, 17:25 UTC

Major Market Movers

ASML Exceeds $500 Billion in Market Value on TSMC's Blockbuster Spending Plans -- Update

15 sty 2026, 23:48 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

15 sty 2026, 23:48 UTC

Market Talk

Nikkei May Decline as Enthusiasm Over Election Eases -- Market Talk

15 sty 2026, 23:40 UTC

Market Talk

Gold Edges Lower Amid Abating Geopolitical Risks -- Market Talk

15 sty 2026, 23:11 UTC

Market Talk

Global Equities Roundup: Market Talk

15 sty 2026, 23:11 UTC

Market Talk

Ryman Healthcare's Resales Remain Key Concern -- Market Talk

15 sty 2026, 23:01 UTC

Market Talk

New Zealand's Economy Enters An Upswing -- Market Talk

15 sty 2026, 22:56 UTC

Market Talk

Earnings

Catalyst Metals Delivers a Beat With Record Gold Output -- Market Talk

15 sty 2026, 22:51 UTC

Market Talk

James Hardie's Plant Closures Could Boost Profit by 2%-3% -- Market Talk

15 sty 2026, 22:19 UTC

Acquisitions, Mergers, Takeovers

Verizon Gets Final California Approval to Secure $9.6 Billion Frontier Deal -- WSJ

15 sty 2026, 21:50 UTC

Market Talk

Earnings

Financial Services Roundup: Market Talk

15 sty 2026, 21:50 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Energy & Utilities Roundup: Market Talk

15 sty 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

15 sty 2026, 21:27 UTC

Earnings

BlackRock Caps 2025 With Record $14 Trillion in Assets -- 3rd Update

15 sty 2026, 21:15 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Global Commodities Roundup: Market Talk

15 sty 2026, 21:11 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Global Equities Roundup: Market Talk

15 sty 2026, 21:11 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Canada Antitrust Watchdog Confirms Review of Canadian Energy Deal -- Market Talk

15 sty 2026, 20:10 UTC

Market Talk

U.S. Natural Gas Futures Settle Mixed -- Market Talk

15 sty 2026, 20:04 UTC

Earnings

These Stocks Are Today's Movers: TSMC, ASML, Goldman, Morgan Stanley, BlackRock, Coinbase, Sandisk, and More -- Barrons.com

15 sty 2026, 20:03 UTC

Market Talk

Oil Futures Fall As Iran Risk Premium Fades -- Market Talk

15 sty 2026, 19:26 UTC

Market Talk

Silver Closes at Fresh High -- Market Talk

15 sty 2026, 18:29 UTC

Major Market Movers

Agenus Falls After $141M Zydus Deal Closes

15 sty 2026, 18:20 UTC

Earnings

Wall Street Powers Nation's Biggest Banks to Record Year -- WSJ

15 sty 2026, 17:56 UTC

Market Talk

Earnings

U.S. Bank Results Look Encouraging for European Peers -- Market Talk

15 sty 2026, 17:20 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Auto & Transport Roundup: Market Talk

15 sty 2026, 17:20 UTC

Market Talk

Health Care Roundup: Market Talk

15 sty 2026, 17:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

15 sty 2026, 17:02 UTC

Acquisitions, Mergers, Takeovers

KBC Group Completes Acquisition of 98.45% Stake in 365.bank From J&T Finance Group

Peer Comparison

Price change

Voyager Therapeutics Inc Forecast

Price Target

By TipRanks

228.36% upside

12 Months Forecast

Average 13.2 USD 228.36%

High 25 USD

Low 8 USD

Based on 7 Wall Street analysts offering 12 month price targets forVoyager Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

7 ratings

Buy

Hold

Sell

Based on 7 analysts giving stock ratings to Voyager Therapeutics Inc - Dist in the past 3 months.

Technical Score

By Trading Central

3.17 / 3.4644Support & Resistance

Recent bearish events outweigh bullish events.

All events are bearish.

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Voyager Therapeutics Inc

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.